<DOC>
	<DOCNO>NCT02875366</DOCNO>
	<brief_summary>This Phase 4 , randomize , double-blind , placebo-controlled , parallel-group study subject age 12 year old CF homozygous F508del-CFTR mutation . This study design evaluate effect LUM/IVA manifestation CF affect exercise tolerance &amp; training .</brief_summary>
	<brief_title>A Study Effects Lumacaftor/Ivacaftor Exercise Tolerance Subjects With Cystic Fibrosis , Homozygous F508del-CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Homozygous F508del CFTR mutation Confirmed diagnosis CF define sweat chloride value â‰¥60 mmol/L quantitative pilocarpine iontophoresis Stable CF disease judge investigator . FEV1 least 40 % great 90 % predict . History comorbidity might confound result study , interfere use CPET assessment , pose additional risk administer study drug subject . Any previous exposure LUM IVA History cardiac arrhythmia , ischemic heart disease , congestive heart failure , clinically significant cardiac condition , medical condition require chronic use beta blocker , nondihydropyridine calcium channel blocker , cardiac medication know affect exercise tolerance . History solid organ hematological transplantation . For subject 18 year age Screening , except bilateral lens removal , select finding screen ophthalmologic examination exclusionary Using expect require concomitant medication prohibit study History alcohol drug abuse , deem investigator , past year , include limited cannabis , cocaine , opiates . Participation investigational drug study within 30 day Screening Visit . Pregnant nursing female ; male female partner pregnant nursing . Colonization organisms associate rapid decline pulmonary status</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>